NCT01260129已完成4 期
Safety and Efficacy of 8mg Once-daily Versus 4mg Twice-daily Silodosin With Lower Urinary Tract Symptoms Suggestive of BPH ; 12-week, Double-blind, Randomized, Comparison, Multi-center Study
JW Pharmaceutical14 个研究点 分布在 1 个国家目标入组 424 人开始时间: 2010年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 424
- 试验地点
- 14
- 主要终点
- I-PSS
研究概览
简要总结
Korea has newly adopted 8mg Silodosin once daily. Against these backdrops, this clinical study is designed to demonstrate that the newly adopted dose is not inferior to the existing dose in its efficacy and safety.
详细描述
Silodosin is a highly selective α1A-adrenoceptor antagonist for the treatment of the signs and symptoms of BPH. 4mg Silodosin twice daily has been approved in Asia including Japan and Korea. In US, 8mg Silodosin once daily with the FDA approval is already available. Korea has newly adopted 8mg Silodosin once daily. Against these backdrops, this clinical study is designed to demonstrate that the newly adopted dose is not inferior to the existing dose in its efficacy and safety. The study used double-blind, random assignment in Korean men with signs and symptoms of BPH for 12 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Patients who have been diagnosed with BPH through digital rectal exam or ultrasonographic findings and meet the following criteria.
- •Outpatients aged 50 or over
- •Patients with a total I-PSS score of 8 or higher and a QoL score of 3 or higher
- •Patients with a prostate volume measured by transabdominal ultrasonography, or TRUS of 20 ml or greater
- •Patients with a maximum urinary flow rate (Qmax_) of 15ml/sec or below (whose a void urinary volume of 120ml or greater)
排除标准
- •Patients with a residual urinary volume of 200ml or greater
- •Patients with a history of prostatectomy
- •Patients with a history of intrapelvic radiation therapy
- •Patients with a history of prostatic hyperthermia
- •Patients with prostate cancer or suspected prostate cancer
- •Patients with complications considered likely to affect urinary passing such as neurogenic bladder, bladder calculus and active urinary tract infection. UTI
- •Patients conducting self-catheterization
- •Patients with renal impairment (serum creatinine of 3.0 mg/dl or greater)
- •Patients with severe heptic disorders (hepatic insufficiency, cirrhosis, jaundice, hepatoma) or with a total bilirubin of 3.0mg/dL or greater or AST/ALT 2.5 times higher than normal level
- •Patients with history of severe arrhythmia, cardiac failure, cardiac infarction, unstable angina, cerebral infarction within 6 months
- •Patients with a history of an allergy to α-blockers
- •Patients with orthostatic hypotension at around screening visit
- •Patients with an experience of other investigational product treatments within 4 weeks form screening visit.
- •Patients with a PSA of 10 or over, Patients with tumor identified by a prostate biopsy with a PSA of 4 or over (For patients taking 5α-reductase inhibitors for more than 3 months are presumed to have double than their actual PSA levels.)
- •Patients who have taken unstable doses of antidepressants within the 3 months or who are expected to take unstable doses during the study
- •Patients who have taken alpha blockers within the 2 weeks from the start of the therapy
- •Patients who have taken unstable doses of 5α-reductase inhibitors within the 3 months from the start of the therapy or who are expected to take unstable doses during the study.
- •Patients disqualified by the investigator.
研究组 & 干预措施
Silodosin 8 mg
Experimental
干预措施: Silodosin (Drug)
Silodosin 4 mg
Experimental
干预措施: Silodosin (Drug)
结局指标
主要结局
I-PSS
时间窗: 12 weeks
Change in I-PSS total score from baseline
次要结局
- I-PSS, Qmax, QoL, ICS Male Questionnaire, goal achievement, Treatment satisfaction question(12 weeks)
研究者
研究点 (14)
Loading locations...
相似试验
已完成
2 期
Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.Abacterial Chronic Prostatitis/Chronic Pelvic Pain SyndromeNCT00740779Watson Pharmaceuticals153
Unknown
2 期
Safety and Efficacy of Silodosin in the Treatment of Premature EjaculationPremature EjaculationNCT02581826Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation40
已完成
4 期
Efficacy of Silodosin in the Treatment of Symptomatic Benign Prostatic Hyperplasia (BPH)Benign Prostatic HyperplasiaNCT04107896Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh141
已完成
1 期
Safety, Tolerability,Pharmacokinetics and Pharmacodynamics of ODM-106 in Healthy VolunteersHealthy Volunteer StudyNCT02393950Orion Corporation, Orion Pharma16
已完成
4 期
Effectiveness and Safety of Silodosin in the Treatment of Benign Prostatic HyperplasiaBenign Prostatic HyperplasiaNCT01757769RECORDATI GROUP1,036